The percentage abundance of sarcomatoid component has a prognostic role in grade 4 non-metastatic clear cell-renal carcinoma
By
Giuseppe Lucarelli
Francesco Lasorsa
Monica Rutigliano
Martina Milella
Marco Spilotros
Antonio d’Amati
Giuseppe Ingravallo
Felice Crocetto
Savio Domenico Pandolfo
Marco Fabiano
Matteo Ferro
Riccardo Autorino
Michele Battaglia
Pasquale Ditonno
April 23, 2025
Clinical Scorecard: Prognostic Significance of Sarcomatoid Component Proportion in Grade 4 Non-Metastatic Clear Cell Renal Carcinoma
At a Glance
Category Detail
Condition Grade 4 non-metastatic clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation Key Mechanisms Sarcomatoid dedifferentiation characterized by epithelial-mesenchymal transition (EMT) leading to aggressive tumor phenotype Target Population Patients with surgically resected localized or locally advanced sarcomatoid ccRCC without visceral metastases Care Setting Surgical oncology and pathology evaluation in tertiary care centers
Key Highlights
Sarcomatoid component presence defines grade 4 ccRCC and is associated with poor prognosis and aggressive disease. Percentage of sarcomatoid component (PSC) stratifies patients into low (<20%) and high (≥20%) sarcomatoid groups with prognostic implications. High sarcomatoid component (≥20%) correlates with larger tumor size, advanced stage, and worse cancer-specific and recurrence-free survival. Guideline-Based Recommendations
Diagnosis
Confirm sarcomatoid features by histopathology with hematoxylin–eosin staining according to 2022 WHO/ISUP grading system. Assess percentage of sarcomatoid component using digital pathology tools and expert uropathologist review. Exclude rhabdoid components to isolate sarcomatoid dedifferentiation. Management
Perform radical nephrectomy with lymph node dissection for localized or locally advanced sarcomatoid ccRCC. Stratify patients based on sarcomatoid component percentage to inform prognosis and potential adjuvant treatment decisions. Monitoring & Follow-up
Implement surveillance with thoraco-abdominal CT or MRI according to EAU guidelines for recurrence detection. Use cancer-specific survival and recurrence-free survival as key endpoints for follow-up. Risks
High sarcomatoid component (≥20%) indicates increased risk of disease recurrence and mortality. Sarcomatoid dedifferentiation is linked to higher tumor stage and aggressive clinical course. Patient & Prescribing Data
Non-metastatic sarcomatoid clear cell RCC patients undergoing surgery
Radical nephrectomy is the mainstay; sarcomatoid component quantification aids risk stratification but specific systemic therapies were not detailed.
Clinical Best Practices
Comprehensive tumor sampling and digital pathology-assisted quantification of sarcomatoid component for accurate grading. Use a 20% sarcomatoid component cutoff to stratify patients into prognostic groups. Multidisciplinary approach involving uropathologists and oncologists for optimal management and follow-up. References
